Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Analyst Robert Burns from H.C. Wainwright reiterated a Hold rating on Zymeworks (ZYME – Research Report) and keeping the price target at ...

NZ Breast Cancer Foundation: New Breast Cancer Wonder Drug Would Be Life-Changing For NZ Women Breast Cancer Foundation NZ ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...

The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...